Granulocyte colony stimulating factor long-acting - Genexine

Drug Profile

Granulocyte colony stimulating factor long-acting - Genexine

Alternative Names: G-CSF-hyFc; GCSF-hFc; GX-G03; GX-G3

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genexine
  • Developer Boryung Pharmaceutical; Genexine; Ilkogen
  • Class Adjuvants; Glycoproteins; Granulocyte colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 02 Mar 2016 Phase-II clinical trials in Neutropenia (Chemotherapy-induced) in Bulgaria (SC) (EudraCT2015-002693-20)
  • 16 Oct 2015 GX G3 licensed to Tasly in China
  • 28 Jan 2015 Genexine completes a phase I trial in Neutropenia (in volunteers) in South Korea (NCT01951027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top